I SongunandMee Joo [15,17]indicated that the loss of EpCAM expression is associated with aggressive tumours, especially in GC patients with stages I and II disease, and these results are consistent with those related to ovarian carcinomas reported in the study of Kim[31]. Here, EPCAM is linked to ovarian carcinoma.